BCC
PCRX icon

Bridge City Capital’s Pacira BioSciences PCRX Stock Holding History

Bridge City Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.1M Buy
402,765
+117,272
+41% +$2.61M 2.52% 6
2025
Q4 		$7.39M Sell
285,493
-25,951
-8% -$617K 2.17% 5
2025
Q3 		$8.03M Buy
311,444
+141,771
+84% +$3.48M 2.14% 4
2025
Q2 		$4.06M Sell
169,673
-2,473
-1% -$62.3K 1.14% 31
2025
Q1 		$4.28M Sell
172,146
-57,050
-25% -$1.37M 1.28% 27
2024
Q4 		$4.32M Sell
229,196
-2,019
-0.9% -$35.4K 1.15% 30
2024
Q3 		$3.48M Buy
231,215
+146,359
+172% +$2.5M 0.96% 42
2024
Q2 		$2.43M Buy
84,856
+22,912
+37% +$652K 0.82% 49
2024
Q1 		$1.81M Buy
+61,944
New +$1.9M 0.66% 79

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return